myeloencephalitis


Also found in: Medical.

myeloencephalitis

[‚mī·ə·lō·in‚sef·ə′līd·əs]
(medicine)
Inflammation of the brain and spinal cord.
Mentioned in ?
References in periodicals archive ?
Clinical and epidemiological characteristics of 162 patients with myeloencephalitis probably caused by Gnathostoma spinigerum.
Two fatal cases of eosinophilic myeloencephalitis a newly recognized disease caused by Gnathostoma spinigerum.
ANOTHER top Kentucky stallion, Woodman, is covering again after undergoing precautionary treatment for the bacterial disorder equine proto- zoal myeloencephalitis (EPM).
IDEXX Pharmaceuticals also has a number of products in the registration process with the FDA, including a nitazoxanide-based product for treatment of equine protozoal myeloencephalitis -- a neurological disease that is believed to affect approximately 200,000 horses in the US; a topical non-steroidal anti-inflammatory for equine use; an insulin product for the treatment of diabetic cats; and a long-acting injectable antibiotic for cats are also in development.
Several neurologic conditions were considered in the differential diagnosis, including other viral encephalomyelitides (rabies, Aujesky disease, Borna disease, EHV-1 myeloencephalopathy, WEEV, and WNV encephalomyelitis), bacterial meningitis, listeriosis, leukoencephalomalacia, lead poisoning, equine protozoal myeloencephalitis, nigropallidal encephalomalacia, botulism, and verminous encephalitis.
Food and Drug Administration has informally told the Company that it is likely to issue an incomplete letter regarding the Company's new animal drug application (NADA) for nitazoxanide, a drug intended for the treatment of equine protozoal myeloencephalitis.
The Company is seeking FDA approval of a number of other drugs for companion animals, including a treatment for equine protozoal myeloencephalitis (EPM), a non-steroidal anti-inflammatory, and a novel, long-acting antibiotic for companion animals.
The new company is a leading-edge veterinary biotechnology company whose first product is the world's only reliable test for equine protozoal myeloencephalitis (EMP), which causes severe damage to horses' central nervous systems.
Food and Drug Administration (FDA) to market and sell NAVIGATOR(R) (32% nitazoxanide) Antiprotozoal Oral Paste, a new treatment for equine protozoal myeloencephalitis (EPM), a progressive, degenerative disease of the central nervous system that can cause serious or even fatal neurological problems in horses.
equine diagnostic laboratory which specializes in testing services for equine protozoal myeloencephalitis (EPM).
EBI's proprietary technology is a highly specific diagnostic test for equine protozoal myeloencephalitis (EPM), an emerging neurologic disease which causes economic loss to the horse industry.